[PDF][PDF] Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer
A Singh, RA Holmes, M Farhangi… - Journal of Nuclear …, 1989 - Soc Nuclear Med
METhOD Patient Selection Five patients with histopathologically proven primary can cer and
radiographic and/or scintigraphic bony metastases werestudiedunderphysiciansIND27865 …
radiographic and/or scintigraphic bony metastases werestudiedunderphysiciansIND27865 …
Samarium—153 EDTMP therapy of disseminated skeletal metastasis
JH Turner, AA Martindale, P Sorby… - European journal of …, 1989 - Springer
Abstract 153 Sm-EDTMP (ethylenediaminetetramethylene phosphonate), prepared from a
kit, was administered to 28 patients in a clinical trial of therapy for painful skeletal …
kit, was administered to 28 patients in a clinical trial of therapy for painful skeletal …
Re-186 (Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies.
HR Maxon, EA Deutsch, SR Thomas, K Libson… - Radiology, 1988 - pubs.rsna.org
Investigation of the biodistribution of subtherapeutic amounts of a new, chromatographically
purified rhenium-186 (tin) hydroxyethylidene diphosphonate radiopharmaceutical have …
purified rhenium-186 (tin) hydroxyethylidene diphosphonate radiopharmaceutical have …
[153Sm] EDTMP: a potential therapy for bone cancer pain
RA Holmes - Seminars in nuclear medicine, 1992 - Elsevier
Reactor-produced samarium-153 (153 Sm) is both a beta and gamma emitter with a
physical half-life of 46.3 hours. When complexed with EDTMP, more than 50% of the …
physical half-life of 46.3 hours. When complexed with EDTMP, more than 50% of the …
Radioactive ion beams for biomedical research and nuclear medical application
GJ Beyer - Hyperfine Interactions, 2000 - Springer
In this article a review is given on the research strategies, on experimental work and
application of ISOLDE produced radionuclides used in the field of biomedicine over a period …
application of ISOLDE produced radionuclides used in the field of biomedicine over a period …
[PDF][PDF] A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186 (Sn)-HEDP
RC Samaratunga, SR Thomas… - Journal of Nuclear …, 1995 - Soc Nuclear Med
Results: Results show a significantdependence on the bone volume fraction and hence on
the histology of the lesion (lytic, blastic or mixed). The uniform lesion model calculations …
the histology of the lesion (lytic, blastic or mixed). The uniform lesion model calculations …
[PDF][PDF] Therapy with Alpha Rays
L Mango, M Pacilio - ARC Journal of Radiology and Medical Imaging, 2016 - academia.edu
Treatment with radioactive isotopes has been the first clinical application of Nuclear
Medicine, when, in the early'40s, the Phosphorus-32 was used for polycythemia and some …
Medicine, when, in the early'40s, the Phosphorus-32 was used for polycythemia and some …
Preparation of a cold kit of 186 Re(Sn)-HEDP
H Bai, X Jin, F Wang, J Du, Y Liu… - Journal of radioanalytical …, 1996 - akjournals.com
The preparation of a cold kit was introduced in the paper, and the effective quantities of the
components (Vc, HEDP and SnCl 2· 2H 2 O) in the kit were determined. At the sametime, the …
components (Vc, HEDP and SnCl 2· 2H 2 O) in the kit were determined. At the sametime, the …
Palliative Strahlentherapie
A Hoederath, K Schüle-Hein, H Sack - Strahlentherapie: Radiologische …, 1996 - Springer
Zusammenfassung Die Optimierung supportiver Behandlungsmaßnahmen führte neben
den Verbesserungen der spezifischen Tumortherapie in den letzten 10–15 Jahren bei der …
den Verbesserungen der spezifischen Tumortherapie in den letzten 10–15 Jahren bei der …
放射性核素治疗骨转移癌的研究进展
蒋宁一 - 同位素, 2001 - tws.xml-journal.net
概述了目前放射性核素治疗骨转移癌的现状及存在的问题. 对一些放射性核素及其标记物在治疗
骨转移癌方面的作用机理, 特性, 使用方法, 临床评价及优缺点进行了评述 …
骨转移癌方面的作用机理, 特性, 使用方法, 临床评价及优缺点进行了评述 …